BioSpace News Archive

Albany NY, United States: Transparency Market Research has published a new report titled, ‘Compression Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

DUBAI, United Arab Emirates, The global bipolar disorder drugs and treatment market share, which was anticipated to be worth US$ 5.9 billion in 2022, is expected to expand to US$ 6.8 billion by 2026, at a CAGR of 3.1 per cent throughout the forecast period.

Seneca Therapeutics, Inc. will be presenting on Wednesday, April 20 at 12:10pm at the World Vaccine Congress in Washington, DC. Seneca Therapeutics’ Senior Immunology Consultant, Michael Lacy, PhD will present a summary of prior research and three clinical trials done utilizing Seneca Valley Virus delivered intravenously as a monotherapy.

Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit.

Oragenics, Inc. announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities.

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has selected 10 of its 15 clinical sites for its Phase 2 clinical trial targeting chronic lumbar disc disease.

Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its first quarter 2022 financial performance in a press release before the market opens on Monday, May 9, 2022.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced the appointments of Christopher Kurtz as Chief Technical Officer and Sarah Mathieson as Senior Vice President, Corporate Affairs.

Ankyra Therapeutics is pleased to announce that it has established a formal Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to pursue basic, translational and clinical research using Ankyra Therapeutics’ emerging anchored immunotherapy pipeline in collaboration with NCI’s Center for Cancer Research (CCR).

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 second quarter ended March 31, 2022, after the closing of the market on May 5, 2022.